KLK3 and prostate carcinoma: In clinically localized prostate cancer, risk stratification (low-, intermediate- and high-risk) is crucial for the management of such a heterogenic disease, and it is based only on clinicopathologic features (i.e., baseline prostate-specific antigen (PSA), Gleason score and clinical stage of the tumor).